BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21206137)

  • 1. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
    Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?
    Park S; Song E; Oh HS; Kim M; Jeon MJ; Kim WG; Kim TY; Shong YK; Kim DM; Kim WB
    Endocrine; 2019 Aug; 65(2):348-356. PubMed ID: 31236779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
    Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
    Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S; Takata K; Arishima T; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Miyauchi A
    Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
    J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term follow up after antithyroid drug treatment in Graves' disease].
    Wille T; Müller B; Noth D; Bürgi U; Diem P
    Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY; Shong MH; Yi KH; Lee HK; Koh CS; Min HK
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.